Chemomab Therapeutics Ltd.

CMMB50

Penny Stock

$1.58arrow_drop_down0.61%-$0.00

Penny Stock

CMMB50

$1.58

arrow_drop_down0.61%-$0.00

Penny Stock

Performance History

Key Stats
Open	$1.60
Prev. Close	$1.57
EPS	-1.06
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$29.60M
PE Ratio	-

	LOW	HIGH
Day Range	1.58	1.68
52 Week Range	0.42	2.55

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-1.06

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Chemomab Therapeutics Ltd. (CMMB)

Chemomab Therapeutics Ltd. (CMMB) is a biopharmaceutical company that specializes in the development of novel therapeutics for the treatment of fibrosis-related diseases. The company's primary focus is on the development of antibody-based therapies that target the growth factors involved in the progression of fibrosis.

One of Chemomab's leading candidates is CM-101, a monoclonal antibody that targets the growth factor known as CCL24. Preclinical studies have shown that CM-101 has the potential to reduce fibrosis and inflammation in various disease models, including liver fibrosis and idiopathic pulmonary fibrosis.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Adi Mor George Ph.D.
Headquarters: Tel Aviv
Employees: 0
Exchange: NASDAQ

add Chemomab Therapeutics Ltd. to watchlist

Keep an eye on Chemomab Therapeutics Ltd.

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Chemomab Therapeutics Ltd. (CMMB) stock price performance year to date (YTD)?

As of the latest data, Chemomab Therapeutics Ltd. (CMMB) has a year-to-date price change of 193.79%. Over the past month, the stock has experienced a price change of -0.32%. Over the last three months, the change has been 36.21%. Over the past six months, the figure is 139.43%.

help

What is Chemomab Therapeutics Ltd.'s (CMMB) price per share?

The current price per share for Chemomab Therapeutics Ltd. (CMMB) is $1.58. The stock has seen a price change of -$0.01 recently, indicating a -0.61% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Chemomab Therapeutics Ltd. (CMMB)?

For Chemomab Therapeutics Ltd. (CMMB), the 52-week high is $2.55, which is 61.39% from the current price. The 52-week low is $0.42, the current price is 276.19% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Chemomab Therapeutics Ltd. (CMMB) a growth stock?

Chemomab Therapeutics Ltd. (CMMB) has shown an average price growth of -2.84% over the past three years. It has received a score of 27 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Chemomab Therapeutics Ltd. as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

Is Chemomab Therapeutics Ltd. (CMMB) a profitable company?

Chemomab Therapeutics Ltd. (CMMB) has a net income of -$24.16M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$25.46M. Furthermore, the EBITDA is -$15.97M.

help

What is the market capitalization of Chemomab Therapeutics Ltd. (CMMB)?

Chemomab Therapeutics Ltd. (CMMB) has a market capitalization of $29.6M. The average daily trading volume is 1.63, indicating the stock's liquidity and investor engagement.

News

CHEMOMAB THERAPEUTICS

CM-101

PRIMARY SCLEROSING CHOLANGITIS

PHASE 2

PHASE 3

Aug 21, 2024

Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

CHEMOMAB THERAPEUTICS

CM-101

FIBRO-INFLAMMATORY DISEASES

Aug 12, 2024

Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update

Jun 27, 2024

Chemomab Therapeutics (CMMB) Upgraded to Buy: Here's What You Should Know

Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference

CLINICAL STUDY

CALENDAR OF EVENTS

Jun 6, 2024

Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference